AstraZeneca's Tezspire Meets Esophagitis Late-Stage Trial Goals

Dow Jones08-27 14:52

AstraZeneca reported positive results from its Phase 3 trial of Tezspire in patients with eosinophilic esophagitis, an inflammatory disorder of the esophagus.

The Cambridge-based pharmaceutical company said Thursday that the drug demonstrated improvements across co-primary and all key secondary endpoints at week 24 of the trial, which were sustained to week 52.

The co-primary endpoints were histologic remission and the frequency and severity of dysphagia--or difficulty swallowing--compared with the placebo. The safety profile of the drug was generally consistent with its approved indications, AstraZeneca added.

The drug is being developed in collaboration with U.S. biotechnology company Amgen.

Tezspire is currently approved for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps in the U.S., EU, China and Japan.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment